428 related articles for article (PubMed ID: 18155328)
1. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
Nakajima A; Kodama T; Morimoto S; Azuma M; Takeda K; Oshima H; Yoshino S; Yagita H; Okumura K
J Immunol; 1998 Aug; 161(4):1901-7. PubMed ID: 9712059
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand.
Liu A; Guardino A; Chinsangaram L; Goldstein MJ; Panicali D; Levy R
Cancer Res; 2007 Jul; 67(14):7037-44. PubMed ID: 17638917
[TBL] [Abstract][Full Text] [Related]
4. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids.
Ziske C; Etzrodt PE; Eliu AS; Gorschlüter M; Strehl J; Flieger D; Messmer D; Schmitz V; Gonzalez-Carmona MA; Sievers E; Brossart P; Sauerbruch T; Schmidt-Wolf IG
Pancreas; 2009 Oct; 38(7):758-65. PubMed ID: 19546834
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
Briones J; Timmerman J; Levy R
Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933
[TBL] [Abstract][Full Text] [Related]
6. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment.
Chen HW; Huang HI; Lee YP; Chen LL; Liu HK; Cheng ML; Tsai JP; Tao MH; Ting CC
Cancer Immunol Immunother; 2002 Aug; 51(6):341-8. PubMed ID: 12111122
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
[TBL] [Abstract][Full Text] [Related]
8. Activated T hybridomas induce upregulation of B7-1 on bystander B lymphoma cells by a contact-dependent interaction utilizing CD40 ligand.
Jones KW; Hackett CJ
Cell Immunol; 1996 Nov; 174(1):42-53. PubMed ID: 8929453
[TBL] [Abstract][Full Text] [Related]
9. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous expression of allogenic class II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity.
Jang YJ; Nam SY; Kim MS; Seong RH; Park YS; Chung YH; Chung HY
Mol Cells; 2002 Feb; 13(1):130-6. PubMed ID: 11911464
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal Echinococcus multilocularis infection in C57BL/6 mice affects CD40 and B7 costimulator expression on peritoneal macrophages and impairs peritoneal T cell activation.
Mejri N; Gottstein B
Parasite Immunol; 2006 Aug; 28(8):373-85. PubMed ID: 16879309
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
13. Limited costimulatory molecule expression on renal tubular epithelial cells impairs T cell activation.
Waeckerle-Men Y; Starke A; Wahl PR; Wüthrich RP
Kidney Blood Press Res; 2007; 30(6):421-9. PubMed ID: 17975322
[TBL] [Abstract][Full Text] [Related]
14. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
[TBL] [Abstract][Full Text] [Related]
15. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity.
Yellin MJ; Sinning J; Covey LR; Sherman W; Lee JJ; Glickman-Nir E; Sippel KC; Rogers J; Cleary AM; Parker M
J Immunol; 1994 Jul; 153(2):666-74. PubMed ID: 7517421
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
Singh NP; Yolcu ES; Taylor DD; Gercel-Taylor C; Metzinger DS; Dreisbach SK; Shirwan H
Cancer Res; 2003 Jul; 63(14):4067-73. PubMed ID: 12874008
[TBL] [Abstract][Full Text] [Related]
17. Quantitative mRNA expression analysis of co-stimulatory molecules in sequential biopsies from heart allografts.
Akdere F; Bock O; Lehmann U; Serinsöz E; Haverich A; Kreipe H; Mengel M
Transpl Int; 2005 Oct; 18(10):1197-202. PubMed ID: 16162107
[TBL] [Abstract][Full Text] [Related]
18. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
19. Prospects for CD40-directed experimental therapy of human cancer.
Tong AW; Stone MJ
Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
[TBL] [Abstract][Full Text] [Related]
20. CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L.
Shinde S; Wu Y; Guo Y; Niu Q; Xu J; Grewal IS; Flavell R; Liu Y
J Immunol; 1996 Oct; 157(7):2764-8. PubMed ID: 8816378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
